In connection to the filling on Form 20-F with the U.S. Securities and Exchange Commission (SEC), Alvotech has published a supplement dated 22 June 2022 to the Company Description, dated 21 June 2022. The Supplement will form part of and must be read and construed in conjunction with the Company
- Debut on Nasdaq follows completion of the company’s business combination with Oaktree Acquisition Corp. II, which included a fully committed and upsized $175 million PIPE raised through top-tier investors at $10.00 per share - Alvotech’s mission is to enhance sustainability of the global
Hukyndra ® offers a comprehensive range of presentations to the EU adalimumab biosimilars market. Adalimumab marks the first molecule introduced through STADA’s partnership with Alvotech to bring biosimilars across immunology, oncology and ophthalmology indications to patients and their caregivers
· Business Combination anticipated to close on or about June 15, 2022. · Ordinary shares of Alvotech expected to trade under the new ticker symbol “ALVO” from June 16, 2022 on The Nasdaq Stock Market in New York and from June 23, 2022 on the Nasdaq First North Growth Market in Iceland.
- The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint. - AVT04 (ustekinumab) is part of a broader pipeline of Alvotech’s biosimilars and biosimilar candidates, which includes AVT02 (adalimumab), a biosimilar to
- Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product Stelara® Reykjavik, ICELAND (May 16, 2022) – Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of
Reykjavik and Los Angeles (May 11, 2022) – Alvotech Holdings S.A. (“ Alvotech S.A. ”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE: OACB), a special purpose acquisition
Alvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company’s capital position and to replace any redeemed capital as part of their proposed merger. Parties agree to reduce the minimum cash condition outlined in the merger agreement, thereby enhancing deal
Upon launch, HUKYNDRA ® will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market. All intellectual-property disputes related to market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved. Reykjavik, Iceland & Bad Vilbel, Germany.
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023. All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including the ITC action brought forth in December 2021. Reykjavik, Iceland (March 8, 2022) — Alvotech